Olanzapine News and Research

RSS
Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Medical cannabis provides relief across dozens of health symptoms, study shows

Medical cannabis provides relief across dozens of health symptoms, study shows

Researchers explore use of antipsychotic medications in older adults following heart surgery

Researchers explore use of antipsychotic medications in older adults following heart surgery

Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes

Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes

Study: Antipsychotic treatment increases body fat and decreases insulin sensitivity in youth

Study: Antipsychotic treatment increases body fat and decreases insulin sensitivity in youth

Study examines link between antipsychotic treatment during pregnancy and gestational diabetes risk

Study examines link between antipsychotic treatment during pregnancy and gestational diabetes risk

New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

Study compares aripiprazole and quetiapine for treatment of schizophrenia

Study compares aripiprazole and quetiapine for treatment of schizophrenia

Antipsychotic drugs may do significantly more harm to Parkinson's disease patients

Antipsychotic drugs may do significantly more harm to Parkinson's disease patients

Long-term lithium exposure does not increase renal dysfunction risk

Long-term lithium exposure does not increase renal dysfunction risk

Lithium can be safe, effective for children suffering from bipolar disorder

Lithium can be safe, effective for children suffering from bipolar disorder

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Added benefit of lurasidone drug not proven for schizophrenia

Added benefit of lurasidone drug not proven for schizophrenia

Endogenous cannabinoids linked to weight gain in people with schizophrenia

Endogenous cannabinoids linked to weight gain in people with schizophrenia

People with first-episode psychosis may benefit from medication treatment changes, study finds

People with first-episode psychosis may benefit from medication treatment changes, study finds

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan releases generic version of Zyprexa Zydis Tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets